Cogent Biosciences, Inc. Common Stock COGT
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-03T22:05:49.530Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:22:53.386728572Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-03T22:05:49.076764+00:00
Cogent Biosciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 36.12 | 74.8% | 18.0% | 27.40 | 77.4% | 13.8% |
| 25Δ | 35.33 | 77.4% | 16.1% | 28.24 | 75.4% | 11.7% |
| 30Δ | 34.29 | 74.1% | 13.2% | 28.97 | 74.7% | 10.1% |
| 35Δ | 33.47 | 72.6% | 11.2% | 29.62 | 74.6% | 8.8% |
| 40Δ | 32.78 | 72.6% | 9.7% | 30.26 | 73.6% | 7.6% |
| 45Δ | 32.13 | 72.4% | 8.3% | 30.88 | 71.1% | 6.3% |
| 50Δ | 31.50 | 71.6% | 7.0% | 31.47 | 70.0% | 5.3% |
| 55Δ | 30.88 | 71.3% | 5.9% | 32.07 | 69.6% | 4.5% |
| 60Δ | 30.26 | 73.2% | 5.1% | 32.79 | 72.6% | 3.9% |
| 65Δ | 29.65 | 73.3% | 4.3% | 33.50 | 73.4% | 3.2% |
| 70Δ | 29.03 | 72.0% | 3.4% | 34.27 | 73.7% | 2.6% |
| 75Δ | 28.33 | 72.4% | 2.7% | 35.16 | 74.7% | 2.0% |
| 80Δ | 27.54 | 73.8% | 2.1% | 36.09 | 74.4% | 1.5% |
20Δ
- Pseudo strike
- 36.12
- IV
- 74.8%
- B/E move
- 18.0%
- Pseudo strike
- 27.40
- IV
- 77.4%
- B/E move
- 13.8%
25Δ
- Pseudo strike
- 35.33
- IV
- 77.4%
- B/E move
- 16.1%
- Pseudo strike
- 28.24
- IV
- 75.4%
- B/E move
- 11.7%
30Δ
- Pseudo strike
- 34.29
- IV
- 74.1%
- B/E move
- 13.2%
- Pseudo strike
- 28.97
- IV
- 74.7%
- B/E move
- 10.1%
35Δ
- Pseudo strike
- 33.47
- IV
- 72.6%
- B/E move
- 11.2%
- Pseudo strike
- 29.62
- IV
- 74.6%
- B/E move
- 8.8%
40Δ
- Pseudo strike
- 32.78
- IV
- 72.6%
- B/E move
- 9.7%
- Pseudo strike
- 30.26
- IV
- 73.6%
- B/E move
- 7.6%
45Δ
- Pseudo strike
- 32.13
- IV
- 72.4%
- B/E move
- 8.3%
- Pseudo strike
- 30.88
- IV
- 71.1%
- B/E move
- 6.3%
50Δ
- Pseudo strike
- 31.50
- IV
- 71.6%
- B/E move
- 7.0%
- Pseudo strike
- 31.47
- IV
- 70.0%
- B/E move
- 5.3%
55Δ
- Pseudo strike
- 30.88
- IV
- 71.3%
- B/E move
- 5.9%
- Pseudo strike
- 32.07
- IV
- 69.6%
- B/E move
- 4.5%
60Δ
- Pseudo strike
- 30.26
- IV
- 73.2%
- B/E move
- 5.1%
- Pseudo strike
- 32.79
- IV
- 72.6%
- B/E move
- 3.9%
65Δ
- Pseudo strike
- 29.65
- IV
- 73.3%
- B/E move
- 4.3%
- Pseudo strike
- 33.50
- IV
- 73.4%
- B/E move
- 3.2%
70Δ
- Pseudo strike
- 29.03
- IV
- 72.0%
- B/E move
- 3.4%
- Pseudo strike
- 34.27
- IV
- 73.7%
- B/E move
- 2.6%
75Δ
- Pseudo strike
- 28.33
- IV
- 72.4%
- B/E move
- 2.7%
- Pseudo strike
- 35.16
- IV
- 74.7%
- B/E move
- 2.0%
80Δ
- Pseudo strike
- 27.54
- IV
- 73.8%
- B/E move
- 2.1%
- Pseudo strike
- 36.09
- IV
- 74.4%
- B/E move
- 1.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 68.01% | |
| 67.68% | |
| 68.06% | |
| 67.43% | |
| 70.77% | |
| 70.79% | |
| 68.67% | |
| 68.34% | |
| 67.78% | |
| 74.14% |
Biotechnology
CORT
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company…
More →COYA
Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company is…
More →CRBP
Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of novel therapies that target the endocannabinoid…
More →CRBU
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in genome editing through its proprietary CRISPR technology, aimed at developing transformative therapies…
More →CRDF
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.
More →CRMD
CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in…
More →